Paul Elliot Mann Sells 81,077 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

Key Points

• CEO Paul Elliot Mann sold a total of 162,153 shares of ASP Isotopes for approximately $1.37 million in early September, reducing his ownership in the company by about 0.99%.
• ASP Isotopes' stock price fell 1.5% to $8.37, with an average volume of 1.9 million shares traded, significantly lower than its average of 4.8 million shares.
• The company reported a loss of ($1.03) EPS for the last quarter, missing estimates by ($0.92), and is expected to post a -0.24 EPS for the current fiscal year.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) CEO Paul Elliot Mann sold 81,077 shares of the business's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $8.39, for a total value of $680,236.03. Following the transaction, the chief executive officer owned 8,084,191 shares in the company, valued at approximately $67,826,362.49. This represents a 0.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Paul Elliot Mann also recently made the following trade(s):

• On Monday, September 8th, Paul Elliot Mann sold 81,076 shares of ASP Isotopes stock. The shares were sold at an average price of $8.53, for a total value of $691,578.28.

ASP Isotopes Stock Down 1.9%

ASP Isotopes stock traded down $0.16 during midday trading on Monday, hitting $8.61. The stock had a trading volume of 1,550,161 shares, compared to its average volume of 3,197,048. The business has a fifty day moving average price of $9.15 and a 200 day moving average price of $7.18. The company has a current ratio of 14.72, a quick ratio of 14.56 and a debt-to-equity ratio of 3.53. ASP Isotopes Inc. has a 12 month low of $2.55 and a 12 month high of $11.68. The stock has a market cap of $791.00 million, a P/E ratio of -14.14 and a beta of 3.35.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%.The business had revenue of $1.20 million during the quarter, compared to the consensus estimate of $1.60 million. Research analysts predict that ASP Isotopes Inc. will post -0.24 EPS for the current year.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group raised their target price on shares of ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $7.75.

Institutional Trading of ASP Isotopes

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASPI. Ameritas Investment Partners Inc. grew its position in shares of ASP Isotopes by 41.2% in the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company's stock valued at $40,000 after purchasing an additional 1,600 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock valued at $41,000 after purchasing an additional 2,548 shares in the last quarter. SBI Securities Co. Ltd. increased its position in ASP Isotopes by 84.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company's stock valued at $44,000 after acquiring an additional 4,299 shares during the period. Tower Research Capital LLC TRC increased its position in ASP Isotopes by 96.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company's stock valued at $80,000 after acquiring an additional 5,353 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of ASP Isotopes in the 4th quarter worth approximately $55,000. 16.80% of the stock is owned by institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.